Do analysts rate SNGX or BCTX?

Soligenix presently has a consensus target price of $6.00, suggesting a potential upside of 1,434.53%. Given Soligenix's stronger consensus rating and higher possible upside, analysts plainly believe Soligenix is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soligenix 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, SNGX or BCTX?

Briacell Therap is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Soligenix N/A N/A -$11.08M -$1.68 N/A Briacell Therap N/A N/A -$26.31M -$7.92 N/A

Is SNGX or BCTX more profitable?

Briacell Therap's return on equity of -153.53% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Soligenix N/A -244.73% -131.22% Briacell Therap N/A -153.53% -129.26%

Is SNGX or LGVN more profitable?

Soligenix has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. Longeveron's return on equity of -202.41% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Soligenix N/A -244.73% -131.22% Longeveron -1,844.49% -202.41% -140.67%

Do analysts recommend SNGX or PLUR?

Soligenix currently has a consensus price target of $6.00, suggesting a potential upside of 1,434.53%. Given Soligenix's stronger consensus rating and higher possible upside, analysts clearly believe Soligenix is more favorable than Pluri. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soligenix 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SNGX or PLUR more profitable?

Soligenix has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Soligenix N/A -244.73% -131.22% Pluri -2,162.08% N/A -106.59%

Is SNGX or NEUP more profitable?

Neuphoria Therapeutics' return on equity of -76.93% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Soligenix N/A -244.73% -131.22% Neuphoria Therapeutics N/A -76.93% -54.76%

Do analysts rate PLRZ or SNGX?

Soligenix has a consensus price target of $6.00, suggesting a potential upside of 1,434.53%. Given Soligenix's stronger consensus rating and higher probable upside, analysts plainly believe Soligenix is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Soligenix 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, PLRZ or SNGX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polyrizon N/A N/A -$3.34M N/A N/A Soligenix N/A N/A -$11.08M -$1.68 N/A

Is PLRZ or SNGX more profitable?

Polyrizon's return on equity of 0.00% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Polyrizon N/A N/A N/A Soligenix N/A -244.73% -131.22%

Soligenix (SNGX) Competitors

$0.39 +0.01 (+2.62%)

Closing price 04:00 PM Eastern

Extended Trading

$0.39 0.00 (-0.77%)

As of 05:24 PM Eastern

Compare

SNGX vs. BCTX, LGVN, PLUR, NEUP, and PLRZ

Should you buy Soligenix stock or one of its competitors? MarketBeat compares Soligenix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Soligenix include Briacell Therap (BCTX), Longeveron (LGVN), Pluri (PLUR), Neuphoria Therapeutics (NEUP), and Polyrizon (PLRZ). These companies are all part of the "pharmaceutical products" industry.

How does Soligenix compare to Briacell Therap?

Soligenix (NASDAQ:SNGX) and Briacell Therap (NASDAQ:BCTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

3.6% of Soligenix shares are owned by institutional investors. Comparatively, 15.4% of Briacell Therap shares are owned by institutional investors. 3.1% of Soligenix shares are owned by company insiders. Comparatively, 0.7% of Briacell Therap shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Briacell Therap is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	N/A	N/A	-$11.08M	-$1.68	N/A
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A

Soligenix presently has a consensus target price of $6.00, suggesting a potential upside of 1,434.53%. Given Soligenix's stronger consensus rating and higher possible upside, analysts plainly believe Soligenix is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Briacell Therap's average media sentiment score of 0.98 beat Soligenix's score of 0.00 indicating that Briacell Therap is being referred to more favorably in the news media.

Company	Overall Sentiment
Soligenix	Neutral
Briacell Therap	Positive

Soligenix has a beta of 1.84, indicating that its stock price is 84% more volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market.

Briacell Therap's return on equity of -153.53% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-244.73%	-131.22%
Briacell Therap	N/A	-153.53%	-129.26%

Summary

Soligenix beats Briacell Therap on 8 of the 12 factors compared between the two stocks.

How does Soligenix compare to Longeveron?

Soligenix (NASDAQ:SNGX) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, Longeveron had 2 more articles in the media than Soligenix. MarketBeat recorded 2 mentions for Longeveron and 0 mentions for Soligenix. Longeveron's average media sentiment score of 1.27 beat Soligenix's score of 0.00 indicating that Longeveron is being referred to more favorably in the news media.

Company	Overall Sentiment
Soligenix	Neutral
Longeveron	Positive

Soligenix has a beta of 1.84, indicating that its share price is 84% more volatile than the broader market. Comparatively, Longeveron has a beta of -0.35, indicating that its share price is 135% less volatile than the broader market.

Soligenix has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. Longeveron's return on equity of -202.41% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-244.73%	-131.22%
Longeveron	-1,844.49%	-202.41%	-140.67%

Soligenix has higher earnings, but lower revenue than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	N/A	N/A	-$11.08M	-$1.68	N/A
Longeveron	$1.22M	18.95	-$22.70M	-$1.13	N/A

3.6% of Soligenix shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 3.1% of Soligenix shares are owned by company insiders. Comparatively, 7.4% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Soligenix currently has a consensus target price of $6.00, indicating a potential upside of 1,434.53%. Longeveron has a consensus target price of $5.50, indicating a potential upside of 643.24%. Given Soligenix's higher possible upside, equities analysts plainly believe Soligenix is more favorable than Longeveron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Longeveron beats Soligenix on 9 of the 15 factors compared between the two stocks.

How does Soligenix compare to Pluri?

Soligenix (NASDAQ:SNGX) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Soligenix currently has a consensus price target of $6.00, suggesting a potential upside of 1,434.53%. Given Soligenix's stronger consensus rating and higher possible upside, analysts clearly believe Soligenix is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Pluri had 1 more articles in the media than Soligenix. MarketBeat recorded 1 mentions for Pluri and 0 mentions for Soligenix. Pluri's average media sentiment score of 1.62 beat Soligenix's score of 0.00 indicating that Pluri is being referred to more favorably in the news media.

Company	Overall Sentiment
Soligenix	Neutral
Pluri	Very Positive

Soligenix has a beta of 1.84, meaning that its share price is 84% more volatile than the broader market. Comparatively, Pluri has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market.

Soligenix has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-244.73%	-131.22%
Pluri	-2,162.08%	N/A	-106.59%

Soligenix has higher earnings, but lower revenue than Pluri. Pluri is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	N/A	N/A	-$11.08M	-$1.68	N/A
Pluri	$1.08M	20.61	-$22.58M	-$4.53	N/A

3.6% of Soligenix shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 3.1% of Soligenix shares are owned by company insiders. Comparatively, 43.2% of Pluri shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Soligenix beats Pluri on 8 of the 15 factors compared between the two stocks.

How does Soligenix compare to Neuphoria Therapeutics?

Soligenix (NASDAQ:SNGX) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

3.6% of Soligenix shares are owned by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 3.1% of Soligenix shares are owned by company insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Neuphoria Therapeutics' return on equity of -76.93% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-244.73%	-131.22%
Neuphoria Therapeutics	N/A	-76.93%	-54.76%

Soligenix has a beta of 1.84, suggesting that its share price is 84% more volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

Soligenix presently has a consensus price target of $6.00, indicating a potential upside of 1,434.53%. Neuphoria Therapeutics has a consensus price target of $21.00, indicating a potential upside of 367.71%. Given Soligenix's higher possible upside, equities research analysts plainly believe Soligenix is more favorable than Neuphoria Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Neuphoria Therapeutics has lower revenue, but higher earnings than Soligenix. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	N/A	N/A	-$11.08M	-$1.68	N/A
Neuphoria Therapeutics	-$13.27K	-1,829.23	-$370K	-$11.06	N/A

In the previous week, Soligenix's average media sentiment score of 0.00 equaled Neuphoria Therapeutics'average media sentiment score.

Company	Overall Sentiment
Soligenix	Neutral
Neuphoria Therapeutics	Neutral

Summary

Soligenix beats Neuphoria Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Soligenix compare to Polyrizon?

Polyrizon (NASDAQ:PLRZ) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Polyrizon has a beta of -1.9, meaning that its stock price is 290% less volatile than the broader market. Comparatively, Soligenix has a beta of 1.84, meaning that its stock price is 84% more volatile than the broader market.

Soligenix has a consensus price target of $6.00, suggesting a potential upside of 1,434.53%. Given Soligenix's stronger consensus rating and higher probable upside, analysts plainly believe Soligenix is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Soligenix	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Polyrizon's average media sentiment score of 0.00 equaled Soligenix'saverage media sentiment score.

Company	Overall Sentiment
Polyrizon	Neutral
Soligenix	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Soligenix	N/A	N/A	-$11.08M	-$1.68	N/A

3.6% of Soligenix shares are owned by institutional investors. 3.1% of Soligenix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Polyrizon's return on equity of 0.00% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Soligenix	N/A	-244.73%	-131.22%

Summary

Soligenix beats Polyrizon on 6 of the 9 factors compared between the two stocks.

Get Soligenix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNGX vs. The Competition

Export

Metric	Soligenix	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.80M	$3.51B	$6.56B	$12.24B
Dividend Yield	N/A	2.30%	2.69%	5.82%
P/E Ratio	-0.23	20.68	25.18	24.00
Price / Sales	N/A	336.82	553.81	120.63
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	0.75	8.26	10.77	6.41
Net Income	-$11.08M	$23.91M	$3.56B	$337.14M
7 Day Performance	-2.74%	3.05%	1.37%	-0.48%
1 Month Performance	0.23%	2.40%	0.81%	0.48%
1 Year Performance	-70.60%	56.35%	30.54%	28.14%

Soligenix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNGX Soligenix	1.8408 of 5 stars	$0.39 +2.6%	$6.00 +1,434.5%	-76.9%	$5.80M	N/A	N/A	20
BCTX Briacell Therap	0.4889 of 5 stars	$2.83 +3.3%	N/A	-89.6%	$24.62M	N/A	N/A	8
LGVN Longeveron	2.9083 of 5 stars	$0.79 -0.3%	$5.50 +598.6%	-30.4%	$24.52M	$1.20M	N/A	20	Positive News Gap Up
PLUR Pluri	0.7589 of 5 stars	$2.25 -3.4%	N/A	-52.2%	$24.28M	$1.34M	N/A	150	Positive News
NEUP Neuphoria Therapeutics	2.6686 of 5 stars	$4.30 +0.2%	$21.00 +388.4%	-27.9%	$23.22M	$15.65M	N/A	N/A	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNGX) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Soligenix (SNGX) Competitors

SNGX vs. BCTX, LGVN, PLUR, NEUP, and PLRZ

How does Soligenix compare to Briacell Therap?

Summary

How does Soligenix compare to Longeveron?

Summary

How does Soligenix compare to Pluri?

Summary

How does Soligenix compare to Neuphoria Therapeutics?

Summary

How does Soligenix compare to Polyrizon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNGX vs. The Competition

Soligenix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Soligenix (SNGX) Competitors

SNGX vs. BCTX, LGVN, PLUR, NEUP, and PLRZ

How does Soligenix compare to Briacell Therap?

Do insiders and institutionals have more ownership in SNGX or BCTX?

Which has higher earnings & valuation, SNGX or BCTX?

Do analysts rate SNGX or BCTX?

Does the media refer more to SNGX or BCTX?

Which has more volatility & risk, SNGX or BCTX?

Is SNGX or BCTX more profitable?

Summary

How does Soligenix compare to Longeveron?

Does the media prefer SNGX or LGVN?

Which has more volatility and risk, SNGX or LGVN?

Is SNGX or LGVN more profitable?

Which has stronger earnings & valuation, SNGX or LGVN?

Do institutionals and insiders believe in SNGX or LGVN?

Do analysts recommend SNGX or LGVN?

Summary

How does Soligenix compare to Pluri?

Do analysts recommend SNGX or PLUR?

Does the media favor SNGX or PLUR?

Which has more volatility & risk, SNGX or PLUR?

Is SNGX or PLUR more profitable?

Which has preferable earnings & valuation, SNGX or PLUR?

Do institutionals & insiders hold more shares of SNGX or PLUR?

Summary

How does Soligenix compare to Neuphoria Therapeutics?

Do institutionals and insiders have more ownership in SNGX or NEUP?

Is SNGX or NEUP more profitable?

Which has more volatility & risk, SNGX or NEUP?

Do analysts rate SNGX or NEUP?

Which has higher earnings and valuation, SNGX or NEUP?

Does the media refer more to SNGX or NEUP?

Summary

How does Soligenix compare to Polyrizon?

Which has more risk & volatility, PLRZ or SNGX?

Do analysts rate PLRZ or SNGX?

Does the media prefer PLRZ or SNGX?

Which has stronger valuation & earnings, PLRZ or SNGX?

Do insiders & institutionals have more ownership in PLRZ or SNGX?

Is PLRZ or SNGX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNGX vs. The Competition

Soligenix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools